Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

VIB, Flanders Interuniversity Institute of Biotechnology. (12/1/16). "Press Release: V-Bio Ventures Closes First Life Sciences Fund, Raising over € 75 Million".

Organisations Organisation V-Bio Ventures Fund 1 ARKIV
  Group V-Bio Ventures
  Organisation 2 European Investment Fund (EIF)
  Group EU (govt)
Products Product fund, biotech / life sciences
  Product 2 business development (state/region)
Index terms Index term V-Bio Ventures–SEVERAL: investment, 201612 final closing w additional €12m bringing total fund size to of over €75m
  Index term 2 Orionis Biosciences–V-Bio Ventures: investment, 201612 existent one of three invesments of V-Bio Ventures (LF)
Persons Person Takke, Christina (V-Bio Ventures 201511 Managing Partner + Co-Founder before Forbion Capital Partners)
  Person 2 Cardoen, Johan (VIB 201501 Managing Director)

V-Bio Ventures announces the final closing of its V-Bio Ventures Fund 1 ARKIV (“V-Bio Ventures”) fund with € 76 million in capital commitments. This successful fundraising makes V-Bio Ventures one of the largest European first time life sciences investment funds.

V-Bio Ventures is a life sciences venture fund that identifies, builds and finances start-up and early-stage companies with high growth potential. The fund works closely with Belgium-based VIB, one of the world’s premier life science institutes. V-Bio Ventures will continue to focus on investments throughout Europe in biopharmaceutical, pharmaceuticals, diagnostics and agricultural sectors, and will build a portfolio of companies drawn from both VIB’s research pipeline and elsewhere.

Experienced investors support V-Bio Ventures

The first closing in November 2015 was supported by the European Investment Fund (EIF) as cornerstone investor as well as by several other investors including PMV-ARKimedes, Korys and KU Leuven. Investors that joined during the final closing include Gimv, SFPI-FPIM, BNP Paribas Fortis Private Equity and Ghent University, allowing the fund to exceed its initial target.

Christina Takke, Managing Partner and co-founder of V-Bio Ventures, comments on this successful closing: “We are excited to welcome such experienced and committed investors to V-Bio Ventures. This investment allows the fund to initiate, nurture and grow promising life sciences businesses in Flanders and beyond.”

Johan Cardoen, Managing Director at VIB added: “No doubt that with this fund size, V-Bio Ventures will become a key partner for VIB and others to finance and grow young innovative biotech companies in our ecosystem.”

Piyush Unalkat, Head of Technology Transfer Investments at EIF, the cornerstone investor commented, “A closing at this level with a well-diversified investor base is testament to both the quality of the entire team as well as their strong ties to VIB, one of the top EU research organisations. With this closing, even more capital is made available to support the translation of science to high potential life science companies which in turn will contribute towards long-term societal benefits for citizens in both the EU and further beyond.”

First successful projects of V-Bio Ventures

V-Bio Ventures has already invested in three promising portfolio companies exemplifying the fund’s investment strategy. These include two VIB spin-out companies, Orionis Biosciences and Confo Therapeutics, as well as the UK-based company Oxular Limited (formerly Precision Ocular Ltd). These companies are active in a range of globally important disease areas including cancer, autoimmune, inflammation, and ophthalmology.

Growing expertise in the V-Bio team

The founding V-Bio Ventures team, consisting of the Managing Partners Christina Takke and Willem Broekaert, has been complemented with two seasoned professionals. Katja Rosenkranz has joined the team as Principal. Katja held senior positions in investment, tech transfer and biotech businesses at Ascenion, Hepawash and Polytechnos. Ward Capoen has joined as Senior Analyst from Candriam Investors Group, where he was responsible for investment analysis of early-stage listed biotech companies.

Record changed: 2017-12-19


Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for V-Bio Ventures

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

» top